Developmental Cancer Therapeutics In the News
Sharad Singhal, Ph.D., research professor in the Department of Medical Oncology and Therapeutics Research, leads investigations focusing on a small molecule that is abundant in the pith of citrus fruit.
The takeaway of foundational research by a City of Hope physician-scientist and his colleagues is that patients with metastatic colorectal cancer and a high tumor mutation score should consider immunotherapy as initial treatment.
City of Hope physician-scientist and his colleagues are looking for ways to provide cancer patients with options that yield better outcomes and are more cost-effective.
Inside Dual Spinal Surgery
City of Hope has received a $2 million gift from leading furniture wholesaler Samson Holding Ltd., Samuel Kuo and Grace Liu to advance surgical oncologist Yuman Fong, M.D.’s pioneering liver cancer research.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research (AACR) annual meeting from March 29 through April 3 in Atlanta.
Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.
Bringing City of Hope cancer services closer to Orange County residents is work that is personal to Frank DiBella, a 73-year-old Newport Beach, California, resident and bladder cancer survivor.
In the three decades since robots first entered the operating room, these increasingly sophisticated machines have helped surgeons perform more than a million procedures, all over the human body.
Now celebrating its 10th year, the Caltech and City of Hope Biomedical Research Initiative continues to change the future of science and medicine.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
The scientists developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses – a two-step immunotherapy that eliminated difficult-to-treat prostate cancer in experimental models
Linda Collins's outlook was bleak, thanks to her triple-negative breast cancer diagnosis, until City of Hope oncologist Yuan Yuan, M.D., Ph.D. helped develop a revolutionary new trial to help her.
This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.
Patients with metastatic kidney cancer who have high rates of distress tend to have poorer overall survival compared to those with low distress, according to a new study by City of Hope researchers.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
City of Hope’s John Zaia, M.D., will lead the development of the phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.
Advanced bladder cancer is particularly difficult to treat. The five-year survival rate for Stage 4 bladder cancer is only about 15 percent. Now, City of Hope researchers have discovered a that a novel drug blocks a key protein that drives the disease.